The EFEMP1 gene: A frequent target for epigenetic silencing in multiple human pituitary adenoma subtypes

Neuroendocrinology

Volumn 98, Issue 3, 2013, Pages 200-211

  Duong, Cuong V ^a   Yacqub Usman, Kiren ^a   Emes, Richard D ^b   Clayton, Richard N ^a   Farrell, William E ^a  

^a KEELE UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Adenoma; Epigenetic; Genome wide; Pituitary

Indexed keywords

FIBULIN 3; GELATINASE A; HISTONE; MATRILYSIN; PROTEIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; ZEBULARINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; DRUG EFFECT; EFEMP1 GENE; ENZYME INHIBITION; EPIGENETICS; GENE; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GH3 CELL LINE; HISTONE MODIFICATION; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPECIES DIFFERENCE;

ADENOMA; ANIMALS; CELL LINE, TUMOR; COHORT STUDIES; EPIGENESIS, GENETIC; EXTRACELLULAR MATRIX PROTEINS; GENE SILENCING; GENE TARGETING; HUMANS; MICE; PITUITARY NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84898456709     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000355624     Document Type: Article

References (45)

1. Melmed S: Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 2003; 112: 1603-1618.
2. Melmed S: Pathogenesis of pituitary tumors. Nat Rev Endocrinol 2011; 7: 257-266.
3. Dudley KJ, Revill K, Clayton RN, Farrell WE: Pituitary tumours: all silent on the epigenetics front. J Mol Endocrinol 2009; 42: 461-468.
4. Emes RD, Farrell WE: Make way for the 'next generation': application and prospects for genome- wide, epigenome-specific technologies in endocrine research. J Mol Endocrinol 2012; 49:R19-R27.
5. Vandeva S, Jaffrain-Rea ML, Daly AF, Tichomirowa M, Zacharieva S, Beckers A: The genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2010; 24: 461-476.
6. Yacqub-Usman K, Richardson A, Duong CV, Clayton RN, Farrell WE: The pituitary tumour epigenome: aberrations and prospects for targeted therapy. Nat Rev Endocrinol 2012; 8: 486-494.
7. Hayward BE, Barlier A, Korbonits M, Grossman AB, Jacquet P, Enjalbert A, et al: Imprinting of the G s α gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 2001; 107:R31-R36.
8. Fedele M, Pierantoni GM, Visone R, Fusco A: E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression. Cell Div 2006; 1: 17.
9. D'Angelo D, Palmieri D, Mussnich P, Roche M, Wierinckx A, Raverot G, et al: Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab 2012; 97:E1128-E1138.
10. Palmieri D, D'Angelo D, Valentino T, De Martino I, Ferraro A, Wierinckx A, et al: Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene 2012; 31: 3857-3865.
11. Dudley KJ, Revill K, Whitby P, Clayton RN, Farrell WE: Genome-wide analysis in a murine Dnmt1 knockdown model identifies epigenetically silenced genes in primary human pituitary tumors. Mol Cancer Res 2008; 6: 1567-1574.
12. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B, et al: Loss of expression of GADD45γ, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab 2002; 87: 1262-1267.
13. Bahar A, Bicknell JE, Simpson DJ, Clayton RN, Farrell WE: Loss of expression of the growth inhibitory gene GADD45γ, in human pituitary adenomas, is associated with CpG island methylation. Oncogene 2004; 23: 936-944.
14. Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A: Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J Clin Endocrinol Metab 2005; 90: 2179-2186.
15. Bahar A, Simpson DJ, Cutty SJ, Bicknell JE, Hoban PR, Holley S, et al: Isolation and characterization of a novel pituitary tumor apoptosis gene. Mol Endocrinol 2004; 18: 1827-1839.
16. Duong CV, Emes RD, Wessely F, Yacqub-Usman K, Clayton RN, Farrell WE: Quantitative, genome-wide analysis of the DNA methylome in sporadic pituitary adenomas. Endocr Relat Cancer 2012; 19: 805-816.
17. Kim YH, Lee HC, Kim SY, Yeom YI, Ryu KJ, Min BH, et al: Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann Surg Oncol 2011; 18: 2338-2347.
18. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, et al: Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012; 31: 4567-4576.
19. De Vega S, Iwamoto T, Yamada Y: Fibulins: multiple roles in matrix structures and tissue functions. Cell Mol Life Sci 2009; 66: 1890-1902.
20. Gallagher WM, Currid CA, Whelan LC: Fibulins and cancer: friend or foe? Trends Mol Med 2005; 11: 336-340.
21. Obaya AJ, Rua S, Moncada-Pazos A, Cal S: The dual role of fibulins in tumorigenesis. Cancer Letters 2012; 325: 132-138.
22. Kim YJ, Yoon HY, Kim SK, Kim YW, Kim EJ, Kim IY, et al: EFEMP1 as a novel DNA methylation marker for prostate cancer: arraybased DNA methylation and expression profiling. Clin Cancer Res 2011; 17: 4523-4530.
23. Hu B, Nandhu MS, Sim H, Agudelo-Garcia PA, Saldivar JC, Dolan CE, et al: Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of notch signaling. Cancer Res 2012; 72: 3873-3885.
24. Seeliger H, Camaj P, Ischenko I, Kleespies A, De Toni EN, Thieme SE, et al: EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res 2009; 7: 189-198.
25. Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, Betz B, et al: Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 2009; 124: 1727-1735.
26. Al-Azzawi H, Yacqub-Usman K, Richardson A, Hofland LJ, Clayton RN, Farrell WE: Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosis. Endocrinology 2011; 152: 364-373.
27. Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, Broome JC, et al: Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metabol 1997; 82: 818-824.
28. Yacqub-Usman K, Duong CV, Clayton RN, Farrell WE: Epigenomic silencing of the BMP-4 gene in pituitary adenomas: a potential target for epidrug-induced re-expression. Endocrinology 2012; 153: 3603-3612.
29. Revill K, Dudley KJ, Clayton RN, McNicol AM, Farrell WE: Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma. Endocr Relat Cancer 2009; 16: 537-548.
30. Jenuwein T, Allis CD: Translating the histone code. Science 2001; 293: 1074-1080.
31. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al: Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-1043.
32. Roh TY, Cuddapah S, Cui K, Zhao K: The genomic landscape of histone modifications in human T cells. Proc Natl Acad Sci USA 2006; 103: 15782-15787.
33. Frost SJ, Simpson DJ, Farrell WE: Decreased proliferation and cell cycle arrest in neoplastic rat pituitary cells is associated with transforming growth factor-β 1 -induced expression of p15/ INK4B. Mol Cell Endocrinol 2001; 176: 29-37.
34. Rowther FB, Richardson A, Clayton RN, Farrell WE: Bromocriptine and dopamine mediate independent and synergistic apoptotic pathways in pituitary cells. Neuroendocrinology 2010; 91: 256-267.
35. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE: Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 2000; 60: 1211-1216.
36. Farrell WE, Clayton RN: Molecular pathogenesis of pituitary tumors. Front Neuroendocrinol 2000; 21: 174-198.
37. Fedele M, Pierantoni GM, Visone R, Fusco A: Critical role of the HMGA2 gene in pituitary adenomas. Cell Cycle 2006; 5: 2045-2048.
38. Sharma S, Kelly TK, Jones PA: Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36.
39. Lecka-Czernik B, Lumpkin CK Jr, Goldstein S: An overexpressed gene transcript in senescent and quiescent human fibroblasts encoding a novel protein in the epidermal growth factor-like repeat family stimulates DNA synthesis. Mol Cell Biol 1995; 15: 120-128.
40. Albig AR, Neil JR, Schiemann WP: Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 2006; 66: 2621-2629.
41. Hu Y, Pioli PD, Siegel E, Zhang Q, Nelson J, Chaturbedi A, et al: EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Mol Cancer 2011; 10: 123.
42. Song EL, Hou YP, Yu SP, Chen SG, Huang JT, Luo T, et al: EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer in vivo. Gynecol Oncol 2011; 121: 174-180.
43. Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS: Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res 2009; 7: 1756-1770.
44. Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Qiyong L, Fujii T, et al: Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumorsuppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol 2010; 17: 923-932.
45. Kim EJ, Lee SY, Woo MK, Choi SI, Kim TR, Kim MJ, et al: Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol 2012; 40: 402-408.